Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03326674
Title Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA)
Acronym CONTESSA
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Odonate Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS


No variant requirements are available.